H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-carrion, C. Boni et al., Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group, Journal of Clinical Oncology, vol.19, issue.10, pp.2596-2606, 2001.
DOI : 10.1200/JCO.2001.19.10.2596

H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-carrion, C. Boni et al., Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group, Journal of Clinical Oncology, vol.21, issue.11, pp.2101-2109, 2003.
DOI : 10.1200/JCO.2003.04.194

P. Goss, J. Ingle, S. Martino, N. Robert, H. Muss et al., A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer, New England Journal of Medicine, vol.349, issue.19, pp.1793-1802, 2003.
DOI : 10.1056/NEJMoa032312

M. Overgaard, M. Jensen, J. Overgaard, P. Hansen, C. Rose et al., Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial, The Lancet, vol.353, issue.9165, pp.1641-1648, 1999.
DOI : 10.1016/S0140-6736(98)09201-0

M. Overgaard, P. Hansen, J. Overgaard, C. Rose, M. Andersson et al., Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy, New England Journal of Medicine, vol.337, issue.14, pp.949-955, 1997.
DOI : 10.1056/NEJM199710023371401

D. Zhou, D. Pompon, and S. Chen, Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening, Cancer Res, vol.50, pp.6949-6954, 1990.

R. Eckert and B. Katzenellenbogen, Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells, Cancer Res, vol.42, pp.139-144, 1982.

E. Thompson, . Jr, and P. Siiteri, Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione, J Biol Chem, vol.249, pp.5364-5372, 1974.

M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Analytical Biochemistry, vol.72, issue.1-2, pp.248-254, 1976.
DOI : 10.1016/0003-2697(76)90527-3

T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, Journal of Immunological Methods, vol.65, issue.1-2, pp.55-63, 1983.
DOI : 10.1016/0022-1759(83)90303-4

B. Fisher, J. Costantino, C. Redmond, E. Fisher, D. Wickerham et al., Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14, JNCI Journal of the National Cancer Institute, vol.86, issue.7, pp.527-537, 1994.
DOI : 10.1093/jnci/86.7.527

B. Fisher, J. Dignam, J. Bryant, and N. Wolmark, Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial, JNCI Journal of the National Cancer Institute, vol.93, issue.9, pp.684-690, 2001.
DOI : 10.1093/jnci/93.9.684

M. Baum, A. Buzdar, J. Cuzick, J. Forbes, J. Houghton et al., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, vol.359, pp.2131-2139, 2002.

M. Baum, A. Buzdar, J. Cuzick, J. Forbes, J. Houghton et al., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses, Cancer, vol.98, pp.1802-1810, 2003.

B. Fisher, M. Bauer, R. Margolese, R. Poisson, Y. Pilch et al., Five-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Segmental Mastectomy with or without Radiation in the Treatment of Breast Cancer, New England Journal of Medicine, vol.312, issue.11, pp.665-673, 1985.
DOI : 10.1056/NEJM198503143121101

C. Osborne, D. Boldt, G. Clark, and J. Trent, Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase, Cancer Res, vol.43, pp.3583-3585, 1983.

W. Sinclair, Cyclic X-Ray Responses in Mammalian Cells in Vitro, Radiation Research, vol.33, issue.3, pp.620-643, 1968.
DOI : 10.2307/3572419

D. Wazer, O. Tercilla, P. Lin, and R. Schmidt-ullrich, Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen, The British Journal of Radiology, vol.62, issue.744, pp.1079-1083, 1989.
DOI : 10.1259/0007-1285-62-744-1079

Y. Berthois, J. Katzenellenbogen, and B. Katzenellenbogen, Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture., Proceedings of the National Academy of Sciences, vol.83, issue.8, pp.2496-2500, 1986.
DOI : 10.1073/pnas.83.8.2496

W. Butler, W. Kelsey, and N. Goran, Effects of serum and insulin on the sensitivity of the human breast cancer cell line MCF-7 to estrogen and antiestrogens, Cancer Res, vol.41, pp.82-88, 1981.

M. Page, J. Field, N. Everett, and C. Green, Serum regulation of the estrogen responsiveness of the human breast cancer cell line MCF-7, Cancer Res, vol.43, pp.1244-1250, 1983.

P. Germain and G. Harbrioux, Modulation of the estradiol-17 beta mitogenic effect on human breast cancer MCF-7 cells by serum albumin in defined medium, Anticancer Res, vol.13, pp.1581-1585, 1993.

M. Gould and K. Clifton, The survival of rat mammary gland cells following irradiation in vivo under different endocrinological conditions, International Journal of Radiation Oncology*Biology*Physics, vol.4, issue.7-8, pp.629-632, 1978.
DOI : 10.1016/0360-3016(78)90185-2

J. Sarkaria, E. Miller, C. Parker, V. Jordan, and R. Mulcahy, 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiatedin vitro, Breast Cancer Research and Treatment, vol.79, issue.2, pp.159-165, 1994.
DOI : 10.1007/BF00666060

E. Cormier and V. Jordan, Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor, European Journal of Cancer and Clinical Oncology, vol.25, issue.1, pp.57-63, 1989.
DOI : 10.1016/0277-5379(89)90051-5

G. Steel and M. Peckham, Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity, International Journal of Radiation Oncology*Biology*Physics, vol.5, issue.1, pp.85-91, 1979.
DOI : 10.1016/0360-3016(79)90044-0

G. Steel, Terminology in the description of drug-radiation interactions, International Journal of Radiation Oncology*Biology*Physics, vol.5, issue.8, pp.1145-1150, 1979.
DOI : 10.1016/0360-3016(79)90634-5

G. Paulsen, T. Strickert, A. Marthinsen, and S. Lundgren, Changes in Radiation Sensitivity and Steroid Receptor Content Induced by Hormonal Agents and Ionizing Radiation in Breast Cancer Cells in Vitro, Acta Oncologica, vol.14, issue.8, pp.1011-1019, 1996.
DOI : 10.3109/02841869609100720

W. Miller, R. Hawkins, and A. Forrest, Significance of aromatase activity in human breast cancer, Cancer Res, vol.42, pp.3365-3368, 1982.

O. Neill, J. Miller, and W. , Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases

O. Neill, J. Elton, R. Miller, and W. , Aromatase activity in adipose tissue from breast quadrants: a link with tumour site, BMJ, vol.296, issue.6624, pp.741-743, 1988.
DOI : 10.1136/bmj.296.6624.741